A 55-year-old man with aggressive glioblastoma achieved remission using personalized treatment based on genetic testing of his tumor, which revealed specific mutations in MDM2 and EGFR genes. According to Gram Research analysis, his treatment combined surgery, radiation, chemotherapy, a targeted drug trial, a ketogenic diet, and metformin. This case demonstrates how genetic testing can help doctors create customized treatment plans for brain cancer patients, though results vary by individual and long-term outcomes remain uncertain.
A 55-year-old man with an aggressive brain cancer called glioblastoma achieved remission using a combination of surgery, radiation, chemotherapy, and a special clinical trial drug, along with dietary changes and metformin. According to Gram Research analysis, his tumor had specific genetic mutations that doctors targeted with personalized treatment strategies. This case report from an international team of cancer experts shows how genetic testing can help doctors choose the best treatments for each patient’s unique cancer, offering hope for better outcomes in this typically difficult-to-treat disease.
Key Statistics
A 2026 case report from an international molecular tumor board documented a 55-year-old man with glioblastoma who achieved remission after receiving personalized treatment targeting MDM2 and EGFR gene amplifications combined with surgery, radiation, chemotherapy, and a PI3K/mTOR inhibitor clinical trial drug.
The patient’s tumor harbored MDM2 amplification, which blocks the p53 tumor-suppressor protein, and EGFR amplification, which promotes cancer cell growth, according to genetic sequencing performed by the WIN International Molecular Tumor Board.
The treatment strategy included a ketogenic diet and metformin alongside conventional therapies, with the international expert team considering personalized neoantigen vaccine therapy and combination MDM2/EGFR inhibitors as potential future options if the cancer returned.
The Quick Take
- What they studied: How doctors can use genetic testing to create personalized treatment plans for patients with glioblastoma, an aggressive type of brain cancer
- Who participated: One 55-year-old man diagnosed with glioblastoma who had specific genetic mutations in his tumor cells
- Key finding: The patient achieved remission after receiving a combination treatment plan tailored to his tumor’s genetic makeup, including surgery, radiation, chemotherapy, a targeted drug trial, dietary changes, and metformin
- What it means for you: Genetic testing of tumors may help doctors choose more effective treatments for brain cancer patients, though this approach is still being studied and results vary by individual
The Research Details
This is a case report, which means doctors documented the medical story of one specific patient in detail. The patient had genetic testing performed on his tumor, which revealed specific mutations that doctors could target with treatment. An international team of cancer experts from 18 organizations across 13 countries reviewed this case and discussed the best treatment options based on the genetic findings. The patient received multiple types of treatment working together: surgery to remove the tumor, radiation therapy to kill remaining cancer cells, chemotherapy drugs, a new experimental drug that targets specific pathways in cancer cells, a special diet (ketogenic diet), and metformin, a medication that may help fight cancer. The doctors also considered a personalized vaccine made from the patient’s own tumor mutations.
This research approach is important because glioblastoma is one of the most aggressive and difficult-to-treat brain cancers. By understanding the specific genetic mutations in each patient’s tumor, doctors can choose treatments that directly target those mutations rather than using a one-size-fits-all approach. This personalized medicine strategy may lead to better outcomes and longer survival times for patients with this devastating disease.
This is a single case report, which means it describes one patient’s experience rather than comparing many patients. While case reports are valuable for showing what is possible and generating new ideas, they cannot prove that a treatment works for everyone. The patient’s success may be due to many factors, including his specific genetic mutations, the combination of treatments, his overall health, and possibly luck. Results in other patients may be very different. However, the involvement of international cancer experts and the detailed genetic analysis add credibility to the observations.
What the Results Show
The patient achieved remission, meaning his cancer went away or became undetectable, following a comprehensive treatment approach. His tumor had two major genetic mutations: MDM2 amplification and EGFR amplification. MDM2 amplification means the tumor had extra copies of a gene that normally helps cancer cells survive by blocking a protective protein called p53. EGFR amplification means the tumor had extra copies of a gene that sends growth signals to cancer cells. The doctors targeted both of these mutations with their treatment plan. The patient received surgery to remove the tumor, followed by radiation and chemotherapy. He also participated in a clinical trial testing a drug that blocks two pathways involved in cancer cell growth (PI3K and mTOR pathways). Additionally, he followed a ketogenic diet, a high-fat, low-carbohydrate diet that may help fight cancer, and took metformin, a diabetes medication that researchers are studying for cancer treatment.
The patient’s tumor also had a mutation in a gene called CDKN2A, which normally helps prevent cancer. The international expert team discussed several backup treatment options in case the cancer returned, including drugs that specifically block EGFR, drugs that block MDM2, and combinations of drugs targeting both EGFR and CDK4/6 pathways. The experts also considered a personalized vaccine made from the patient’s own tumor mutations, which trains the immune system to recognize and attack cancer cells. They noted that some immune-boosting treatments might actually make certain brain cancers worse in patients with EGFR and MDM2 mutations, so careful monitoring would be needed.
Glioblastoma has historically been one of the most difficult cancers to treat, with median survival times of around 12 to 15 months even with standard treatment. This case demonstrates the emerging field of precision oncology, where doctors use genetic testing to personalize treatment. Previous research has shown that EGFR and MDM2 mutations are common in glioblastoma, but targeting these specific mutations with combination therapies is still relatively new. The combination of multiple treatment approaches, including a clinical trial drug and dietary intervention, represents an evolving strategy that goes beyond traditional treatment alone.
This is a single case report describing one patient, so we cannot know if these results would work for other patients with similar mutations. The patient received multiple treatments at once, so it is unclear which treatment or combination of treatments was most responsible for the remission. The long-term outcome is unknown, as cancer can return months or years later. The patient may have had factors that made him more likely to respond well to treatment, such as younger age, good overall health, or specific characteristics of his tumor. Results in other patients may be very different. Additionally, some of the treatments discussed, such as the personalized vaccine and certain drug combinations, are still experimental and not yet approved for routine use.
The Bottom Line
Patients with glioblastoma should ask their doctors about genetic testing of their tumor to identify specific mutations. If mutations like EGFR or MDM2 are found, discuss whether targeted drugs designed to block these mutations might be appropriate. Consider asking about clinical trials testing new combination therapies. Discuss whether dietary approaches like a ketogenic diet and medications like metformin might complement standard treatment. These recommendations are based on emerging research and should be discussed with your medical team, as individual cases vary significantly.
This case is most relevant to patients with glioblastoma or other aggressive brain cancers, their families, and their doctors. It is also important for cancer researchers and oncologists interested in precision medicine approaches. People with other types of cancer that have EGFR or MDM2 mutations may find this case informative, though treatment strategies differ by cancer type. This case is less directly relevant to people without cancer, though it demonstrates advances in personalized medicine that may eventually benefit many diseases.
Glioblastoma typically progresses quickly, so treatment decisions need to happen within weeks. If a patient achieves remission like this patient did, the goal is to maintain that remission for as long as possible. However, glioblastoma often returns, sometimes within months or years. Patients should expect ongoing monitoring with imaging and clinical visits. Any benefits from personalized treatment approaches may take weeks to months to become apparent through imaging studies and clinical assessment.
Frequently Asked Questions
What is glioblastoma and why is it so hard to treat?
Glioblastoma is an aggressive brain cancer that grows quickly and spreads easily through the brain. It is difficult to treat because cancer cells develop mutations that help them survive standard treatments. Genetic testing can now identify these specific mutations, allowing doctors to use targeted drugs designed to block them.
Can genetic testing help choose better cancer treatments?
Yes, genetic testing of tumor cells can reveal specific mutations that doctors can target with personalized drugs. This case showed one patient achieving remission using treatment tailored to his tumor’s genetic profile, though results vary by individual and more research is needed.
Does the ketogenic diet really help fight brain cancer?
The ketogenic diet is being studied as a potential complement to cancer treatment, and this patient used it alongside standard therapies. However, this is a single case, so we cannot confirm the diet alone caused the remission. Always discuss dietary changes with your medical team before starting.
What are MDM2 and EGFR mutations in cancer?
MDM2 and EGFR are genes that, when mutated or amplified in cancer cells, help tumors grow and survive. MDM2 mutations block protective proteins, while EGFR mutations send constant growth signals. Drugs targeting these mutations may slow or stop cancer growth in some patients.
Is this treatment available for all glioblastoma patients?
This patient received a combination of standard treatments plus an experimental clinical trial drug. Not all patients have the same genetic mutations, so personalized treatment plans vary. Ask your oncologist about genetic testing and whether clinical trials might be appropriate for your specific case.
Want to Apply This Research?
- Track treatment dates, types, and side effects in a timeline. Record imaging results and tumor marker levels if available. Monitor energy levels, cognitive function, and any new symptoms weekly using a simple 1-10 scale to detect changes early.
- Work with your medical team to implement dietary changes like a ketogenic diet if recommended. Set reminders for all medications including metformin and any clinical trial drugs. Schedule regular follow-up appointments and imaging studies. Keep detailed notes on how you feel and any side effects to share with your doctors.
- Maintain a health journal documenting treatment dates, medication adherence, diet compliance, and symptom changes. Record imaging results and doctor visit notes. Track side effects and their severity. Share this information regularly with your oncology team to help guide ongoing treatment decisions and catch any changes early.
This case report describes one patient’s experience and should not be considered proof that these treatments work for everyone with glioblastoma. Results vary significantly based on individual factors, tumor characteristics, and genetic mutations. Some treatments discussed, including the clinical trial drug and personalized vaccine, are experimental and not yet approved for routine use. Always consult with your oncology team before making any treatment decisions. This information is for educational purposes and does not replace professional medical advice. Glioblastoma is a serious condition requiring care from qualified medical professionals.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.